Myocardial Infarction in Chronic Myeloid Leukemia: Results from Nationwide Readmission Database
Conclusion This analysis showed no statistically significant difference in mortality, 30-day readmission, and complication rates post PCI between CML and non-CML patients. However, interestingly, CML patients may experience lower coronary artery dissection and ischemic stroke rates than those without CML diagnosis.PMID:38705141 | DOI:10.1159/000539149 (Source: Oncology)
Source: Oncology - May 5, 2024 Category: Cancer & Oncology Authors: Elrazi A Ali Neel Patel Mazin Khalid Rasha Kaddoura Madhumathi Kalavar Jacob Shani Mohamed Yassin Source Type: research
Comprehensive Genomic Characterization in Ovarian Low-Grade and chemosensitive and chemoresistant High-Grade Serous Carcinomas
CONCLUSIONS: These results suggest that very low TMB and MYC, CCNE1 and AKT2 gains in SOC patients may be biomarkers related to platinum treatment efficacy. Thorough genomic characterization of SOCs prior to treatment might lead to more specific platinum-based chemotherapy therapy strategies.PMID:38697030 | DOI:10.1159/000538948 (Source: Oncology)
Source: Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Carolina Jaliffa Uwe Rogel Indrani Sen Gad Singer Source Type: research
Comprehensive Genomic Characterization in Ovarian Low-Grade and chemosensitive and chemoresistant High-Grade Serous Carcinomas
CONCLUSIONS: These results suggest that very low TMB and MYC, CCNE1 and AKT2 gains in SOC patients may be biomarkers related to platinum treatment efficacy. Thorough genomic characterization of SOCs prior to treatment might lead to more specific platinum-based chemotherapy therapy strategies.PMID:38697030 | DOI:10.1159/000538948 (Source: Oncology)
Source: Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Carolina Jaliffa Uwe Rogel Indrani Sen Gad Singer Source Type: research
Comprehensive Genomic Characterization in Ovarian Low-Grade and chemosensitive and chemoresistant High-Grade Serous Carcinomas
CONCLUSIONS: These results suggest that very low TMB and MYC, CCNE1 and AKT2 gains in SOC patients may be biomarkers related to platinum treatment efficacy. Thorough genomic characterization of SOCs prior to treatment might lead to more specific platinum-based chemotherapy therapy strategies.PMID:38697030 | DOI:10.1159/000538948 (Source: Oncology)
Source: Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Carolina Jaliffa Uwe Rogel Indrani Sen Gad Singer Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Erratum
Oncology. 2024 Mar 28:1. doi: 10.1159/000538352. Online ahead of print.NO ABSTRACTPMID:38547856 | DOI:10.1159/000538352 (Source: Oncology)
Source: Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
